Abstract
The SARS-CoV-2 variant of concern Omicron was first detected in Italy in November 2021. Data from three genomic surveys conducted in Italy between December 2021 and January 2022 suggest that Omicron became dominant in less than one month (prevalence on January 3: 78.6%-83.8%) with a doubling time of 2.7–3.1 days. The mean net reproduction number rose from about 1.15 in absence of Omicron to a peak of 1.83 for symptomatic cases and 1.33 for hospitalized cases, while it remained stable for critical cases.
Competing Interest Statement
Marco Ajelli has received consultancy fees from Seqirus. None of those research funding is related to COVID-19. All other authors declare no competing interests.
Funding Statement
This study was funded by EU grant 874850 MOOD (catalogued as MOOD 020), Fondazione Valorizzazione Ricerca Trentina (VRT) and project COVIDVAX.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Istituto Superiore di Sanita' obtained an ethical approval from its IRB (https://www.iss.it/comitato-etico) for sequencing SARS-CoV-2 genomes on clinical samples (ref. PRE BIO CE n.26259, July 29, 2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Genomic SARS-CoV-2 National Surveillance Working Group: Alessandra Lo Presti, Stefano Morabito, Gabriele Vaccari, Ilaria Di Bartolo, Arnold Knijn, Luca De Sabato, Liborio Stuppia, Giovanni Savini, Antonio Picerno, Teresa Lopizzo, Domenico Dell’Edera, Pasquale Minchella, Francesca Greco, Giuseppe Viglietto, Maria Teresa Fiorillo, Luigi Atripaldi, Antonio Limone, Davide Cacchiarelli, Pierlanfranco D’Agaro, Danilo Licastro, Stefano Pongolini, Tiziana Lazzarotto, Giada Rossini, Vittorio Sambri, Giorgio Dirani, Silvia Zannoli, Paola Affanni, Maria Eugenia Colucci, Maria Rosaria Capobianchi, Patricia Alba, Alice Massacci, Carlo Federico Perno, Maurizio Sanguinetti, Bianca Bruzzone, Giancarlo Icardi, Flavia Lillo, Andrea Orsi, Elena Pariani, Fausto Baldanti, Maria Rita Gismondo, Valeria Micheli, Fabrizio Maggi, Arnaldo Caruso, Ferruccio Ceriotti, Maria Beatrice Boniotti, Ilaria Barbieri, Alice Nava, Erminio Torresani, Fabiana Cro, Enzo Boeri, Marina Noris, Giulia Bassanini, Claudio Farina, Marco Arosio, Sergio Malandrin, Annalisa Cavallero, Patrizia Bagnarelli, Stefano Menzo, Silvio Garofalo, Massimiliano Scutellà, Elisabetta Pagani, Lucia Collini, Valeria Ghisetti, Silvia Brossa, Giuseppe Ru, Elena Bozzetta, Maria Chironna, Antonio Parisi, Salvatore Rubino, Caterina Serra, Gabriele Ibba, Giovanna Piras, Giuseppe Mameli, Ferdinando Coghe, Francesco Vitale, Fabio Tramuto, Guido Scalia, Concetta Ilenia Palermo, Giuseppe Mancuso, Teresa Pollicino, Francesca Di Gaudio, Stefano Vullo, Stefano Reale, Maria Grazia Cusi, Gian Maria Rossolini, Mauro Pistello, Antonella Mencacci, Barbara Camilloni, Silvano Severini, Massimo Di Benedetto Terregino Calogero, Isabella Monne, Valeria Biscaro.
Italian Integrated Surveillance of COVID-19 Study Group: Del Manso Martina, Spuri Matteo, Sacco Chiara, Fabiani Massimo, Bressi Marco, Mateo-Urdiales Alberto, Vescio Maria Fenicia.
Data Availability
All data produced in the present study are available upon reasonable request to the authors